John Allan, MD, Weill Cornell Medicine, New York, NY, highlights the upcoming advances in the field of chronic lymphocytic leukemia (CLL) at ASH 2020. The field is now moving away from monotherapies and sequencing type approaches to optimizing how best to combine existing therapies such as Burton’s tyrosine kinase (BTK) inhibitors, venetoxclax, and anti-CD20 antibodies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.